What is GHRP-6?
GHRP-6 stands for growth hormone-releasing peptide-6. It came out of work in the 1970s and 1980s by a team led by Cyril Bowers, who found that modified versions of opioid-like peptides could trigger growth hormone release. At first no one knew which receptor these peptides acted on. Work on these peptides and related compounds led scientists to identify the receptor in the mid-1990s, and in 1999 researchers discovered ghrelin, the stomach hormone that naturally activates it.
GHRP-6 belongs to the GHRP family, which also includes GHRP-2, hexarelin and ipamorelin. MK-677 (ibutamoren) acts on the same receptor but is a small molecule, not a peptide. Over the decades GHRP-6 has served mainly as a research tool, helping scientists map how the brain, stomach and pituitary work together to control growth hormone.
How does GHRP-6 work?
GHRP-6 mimics ghrelin by activating the growth hormone secretagogue receptor in the pituitary gland and the hypothalamus. In the pituitary, this prompts growth hormone release directly. In the hypothalamus, it appears to strengthen the brain's own GHRH signal and counter somatostatin, the hormone that holds growth hormone back. Because ghrelin is also a hunger signal, activating the same receptor tends to raise appetite noticeably.
Human studies found that GHRP-6 and GHRH work together. Given at the same time, they produced a larger growth hormone release than either alone, and this synergy depends on a normal connection between the hypothalamus and pituitary. This is why GHRPs are often discussed alongside GHRH analogs such as sermorelin or CJC-1295.
GHRP-6 vs ipamorelin and other GHRPs
All GHRPs act on the same ghrelin receptor, but they differ in side effects. GHRP-6, GHRP-2 and hexarelin can all cause small rises in cortisol and prolactin, with GHRP-2 and hexarelin often described as stronger on these effects. Ipamorelin was developed later and, in animal studies, released growth hormone without notable rises in cortisol. GHRP-6's most distinctive feature is hunger, which is why it tends to come up in the context of weight gain. No modern trials have compared these peptides on outcomes like muscle or fat.
What has research looked at?
The effect of GHRP-6 on growth hormone in humans is well documented, and its effect on appetite is widely reported. Claims about muscle growth, memory or anti-aging rest on animal studies, theory or user reports, and there are no modern human trials testing those outcomes in healthy adults.
- Growth hormone release in humans
- Human studies from the 1980s and 1990s showed that GHRP-6 reliably raises growth hormone, with a larger effect when combined with GHRH.
- Testing the pituitary
- Researchers have used GHRP-6 combined with GHRH as a test of how much growth hormone the pituitary can release, including in adults with suspected deficiency.
- Appetite
- Animal studies found increased food intake, and people commonly report strong hunger. Formal trials of it for poor appetite are limited.
- Heart and tissue protection
- Animal and lab studies have tested whether GHRP-6 protects the heart, liver and other tissues after injury such as interrupted blood flow, and some reported less damage. This has not been confirmed in human trials.
- Skin wounds and scarring
- A few animal studies have looked at skin wounds and scar formation. The evidence is early and limited.
Side effects and cautions
Short human studies, mostly designed to measure hormone levels, describe GHRP-6 as generally well tolerated, but long-term safety has not been studied in any group. Its side effects reflect both the growth hormone it releases and its ghrelin-like action on appetite and other hormones. Talk to a qualified clinician before making decisions about any growth hormone-related compound.
- Strong hunger
- A marked rise in appetite is the best-known effect and can be unwanted for anyone not trying to gain weight.
- Cortisol and prolactin
- GHRP-6 can cause small, short-lived rises in cortisol and prolactin.
- Fluid and joints
- Higher growth hormone can cause water retention, swelling, joint aches and tingling in the hands.
- Blood sugar
- Higher growth hormone can reduce insulin sensitivity, which matters for people with or at risk of diabetes.
- Cancer history
- Because IGF-1 promotes cell growth, compounds that raise it are generally avoided by people with active cancer, and any past history of cancer calls for careful review.
Further reading
This page summarizes the research in plain words. To read the studies yourself:
- Published studies on GHRP-6 PubMed, US National Library of Medicine
